Innate Pharma S.A.

Thank you for standing by and welcome to the Innate Pharma first quarter 2024 financial results and business update call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question again, press the star one. Thank you. I'd now like to turn the call over to Henry Wheeler, Vice President, Investor Relations and Communications. You may begin.

Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release for our Q1 2024 business update and financial results. We look forward to highlighting the progress made during the quarter to date, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of the website. On slide two, before we start, I'd like to remind you that we'll make forward-looking statements regarding our financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. On slide three, on today's call, we'll be joined by Hervé Braille, interim chief executive officer. Then we have Sonia Carantino, chief medical officer, who will cover updates on the Kutumab and IPH 6501. We'll then hand the call to Yanis Morel, Chief Operating Officer, who will then discuss our ANCET and ADC platform updates. Arvind Sood, EVP US Operations, will wrap and close. We also have Frederick Lombard on the call for Q&A. Hervé, I now hand the call over to you.

Thank you, Henry. Turning to slide four, I'd like to remind you of our strategy. Our ambition is to develop innovative drug candidates that contribute to transform cancer care through a strong pipeline of differentiated antibody-derived drug candidates. We look to drive value from our early R&D efforts through later stage partnerships where and when it makes sense to do so. Our business model is centered around three key priorities. Firstly, we look to create near-term value driven by our lead proprietary product candidate, Lacutamab, which, as you know, is in development for T-cell lymphoma, and with top-line MF data coming at ASCO this year. As a reminder, our focus remains to leverage the value of our products as much as possible, which will further validate our science and offer capital that we can reinvest to advance our proprietary products. products and R&D engine. With the latest data in hand, we will assess the best path forward to maximize the potential of this asset Lakota map. We continue to fuel our pipeline and create longer-term value by leveraging our antibody engineering capabilities and our expertise in biology to develop innovative molecules with a primary focus on our multi-specific NK-cell engager. That's the platform called Enquete. We are pleased to see continuous progress with our partner Sanofi presenting various updates for the lead Enquete candidates which has recently been transitioned from phase one to phase two. We are also pleased to see our lead proprietary on-ket IPH6501 starting phase one trials. As we develop antibody targets for our on-ket platform, we recognize some of these targets might be more applicable for ADC technology, and we have further details in our ADC pipeline today presented by Yanis. Finally, we are building a strong and sustainable foundation for our business with various partnerships across industry and academia. Obviously, our AstraZeneca partnership is of utmost importance with Mona Lisa continuing development in lung cancer. Next slide. The slide six illustrates the variety of approaches that we have. I will now move to slide six to the portfolio. Slide six is a summary of our pipeline, which shows how we continue to translate our science into a robust portfolio of proprietary and partnered assets. It also illustrates how we are executing against our strategy with our lead proprietary assets like LakutaMap, Onket, and with the emerging assets ADC supported by partner products with AstraZeneca, Sanofi, and Takeda from late to early stage development. We anticipate a series of potential clinical data readouts on Catalyst in the upcoming couple of years as our R&D engine looks to leverage our scientific know-how to create a sustainable business. Let's move to the next slide. In ASCO, we'll have, in ASCO 2024, an important abstract being published. This comprises the top-line data from the LACUTAMAB telomac trial in mycosis fungoides. IPH6501 will be published with two posters, one in trial and progress on a preclinical assessment of IPH6501. on eventually two Monalizumab posters with updated phase two cost results in stage three, unresectable in SLC, on the phase two in extensive stage SCLC trial. I would like now to pass the call over to Sonia, who will review the progress made with our portfolio, starting with Leketamab, our most advanced proprietary asset.